Tenofovir Alafenamide

Only available in combination formulations for HIV treatment. Available as "Vemlidy" for hepatitis B treatment.

ARV U.S. Brand Name
Vemlidy
ARV Abbreviation(s)
TAF
U.S. FDA Label
Tenofovir alafenamide Labeling (Package Insert)
ARV Class
Nucleoside reverse transcriptase inhibitors
First U.S. Approval
U.S. Manufacturer
Gilead Sciences
Generic Available?
No
Other Reference Links
HIV Clinical Info Drug Database
FDCs
Bictegravir / Emtricitabine / Tenofovir alafenamide
Darunavir / Cobicistat / Emtricitabine / Tenofovir alafenamide
Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide
Emtricitabine / Rilpivirine / Tenofovir alafenamide
Emtricitabine / Tenofovir alafenamide
Assistance Programs
Gilead Advancing Access
Displaying 1 - 26 of 26
Interaction Color Code Clinical Bottom Line Clinical Effects Drug 1 effect Drug 2 dose Drug 2 effect Management
Lenacapavir Tenofovir alafenamide Green: Administer standard doses Administer standard doses

No clinically significant effect expected

Not reported

 25 mg x 1

TAF AUC increased 32%; Cmax increased 24%. TFV AUC increased 47%; Cmax increased 23%
Tenofovir alafenamide CBZ 725 Red: Avoid combination Do not coadminister: Reduced levels of TAF

Potential decrease in antiretroviral efficacy

Cmax decreased 57%, AUC decreased 55%

 300 mg BID

Not reported

Contraindicated. Use alternative agents.
Tenofovir alafenamide St. John's Wort (Hypericum perforatum) 724 Red: Avoid combination Do not coadminister: Potential for reduced levels of TAF

Potential decrease in antiretroviral efficacy

Not studied

Not studied

Contraindicated. Use alternative agents.
Tenofovir alafenamide RPT 723 Red: Avoid combination Do not coadminister: Potential for reduced levels of TAF

Potential decrease in antiretroviral efficacy

Not studied

Not studied

Contraindicated. Use alternative agents.
Tenofovir alafenamide Primidone 722 Red: Avoid combination Do not coadminister: Potential for reduced levels of TAF

Potential decrease in antiretroviral efficacy

Not studied

Not studied

Contraindicated. Use alternative agents.
Tenofovir alafenamide Phenytoin 721 Red: Avoid combination Do not coadminister: Potential for reduced levels of TAF

Potential decrease in antiretroviral efficacy

Not studied

Not studied

Contraindicated. Use alternative agents.
Tenofovir alafenamide Phenobarbital 720 Red: Avoid combination Do not coadminister: Potential for reduced levels of TAF

Potential decrease in antiretroviral efficacy

Not studied

Not studied

Contraindicated. Use alternative agents.
Tenofovir alafenamide Oxcarbazepine 719 Red: Avoid combination Do not coadminister: Potential for reduced levels of TAF

Potential decrease in antiretroviral efficacy

Not studied

Not studied

Contraindicated. Use alternative agents.
Tenofovir alafenamide RIF 718 Red: Avoid combination Do not coadminister: Potential for reduced levels of TAF

Potential decrease in antiretroviral efficacy

Dosed once: AUC decreased 55%; dosed twice: AUC decreased 14%

Not studied

Contraindicated. Use alternative agents.
Tenofovir alafenamide RFB 717 Red: Avoid combination Do not coadminister: Potential for reduced levels of TAF

Potential decrease in antiretroviral efficacy

Not studied

Not studied

Contraindicated. Use alternative agents.
Tenofovir alafenamide Adefovir 716 Red: Avoid combination Do not coadminister: Potential for increased levels of TAF

Potential for increased renal adverse effects

Not studied

Not studied

Contraindicated. Use alternative agents.
Tenofovir alafenamide SOF/VEL 715 Green: Administer standard doses Administer standard doses

Cmax decreased 20%, AUC decreased 13%

 400 / 100mg once daily

Sofosbuvir: Cmax increased 23%, AUC increased 37%; Sofosbuvir metabolite: Cmax increased 29%, AUC increased 48%, Cmin increased 58%; velpatasvir: Cmax increased 30%, AUC increased 50%, Cmin increased 60%
Tenofovir alafenamide SOF/VEL/VOX 714 Green: Administer standard doses Administer standard doses

Cmax decreased 21%; AUC decreased 7%

 400 / 100 / 100mg + 100mg voxilaprevir once daily

Sofosbuvir Cmax increased 14%, AUC increased 9%. Velpatasvir Cmax decreased 4%, AUC decreased 4%, Cmin decreased 6%. Voxilaprevir Cmax decreased 10%, AUC decreased 9%, Cmin decreased 3%
Tenofovir alafenamide SOF/VEL/VOX 713 Green: Administer standard doses Administer standard doses

Cmax increased 28%, AUC increased 57%

 400 / 100 / 100 + 100 once daily

Sofosbuvir Cmax increased 14%, AUC increased 9%. Velpatasvir Cmax decreased 4%, AUC decreased 4%, Cmin decreased 6%. Voxilaprevir Cmax decreased 10%, AUC decreased 9%, Cmin decreased 3%
Tenofovir alafenamide EFV 712 Green: Administer standard doses Administer standard doses

Cmin decreased 22%, AUC decreased 14%

 600 mg once daily

Not studied
Tenofovir alafenamide LDV/SOF 711 Green: Administer standard doses Administer standard doses

Cmax decreased 10%; AUC decreased 14%

 90 / 400 mg once daily

Not reported
Tenofovir alafenamide EE/NGM 710 Green: Administer standard doses Administer standard doses

Not studied

 NGM 0.180 / 0.215 / 0.250mg once daily with EE 0.025mg once daily

Norgestromin: Cmax increased 17%, AUC increased 12%, Cmin increased 16%; norgestrel: Cmax increased 10%, AUC increased 9%, Cmin increased 11%; EE: Cmax increased 22%, AUC increased 11%, Cmin increased 2%
Tenofovir alafenamide Midazolam 709 Green: Administer standard doses Administer standard doses

Not studied

 2.5mg once daily (PO); 1mg once daily (IV)

midazolam (2.5mg PO): Cmax increased 2%, AUC increased 12%; midazolam (1mg IV): Cmax decreased 1%, AUC increased 8%
Tenofovir alafenamide LDV/SOF 708 Green: Administer standard doses Administer standard doses

Cmax increased 3 - 17%, AUC increased 27-32%

 90 / 400 mg once daily

Ledipasvir: Cmax increased 1%, AUC increased 2%, Cmin increased 2%; sofosbuvir: Cmax decreased 4%, AUC increased 5%; sofosbuvir metabolite: Cmax 8%, AUC increased 8%, Cmin increased 10%
Tenofovir alafenamide DRV/c 707 Green: Administer standard doses Administer standard doses

Cmax decreased 7%, AUC decreased 2%

 800 / 150 mg once daily

Cmax increased 2%, AUC decreased 1%, Cmin decreased 3%
Tenofovir alafenamide DTG 706 Green: Administer standard doses Administer standard doses

Cmax increased 24%, AUC increased 19%

 50 mg once daily

Cmax increased 15%, AUC increased 2%, Cmin increased 5%
Tenofovir alafenamide Sertraline 705 Green: Administer standard doses Administer standard doses

AUC decreased 4%

 50 mg once daily

Cmax increased 14%, AUC increased 9%
Tenofovir alafenamide RPV 704 Green: Administer standard doses Administer standard doses

Cmax increased 1%, AUC increased 1%

 25 mg once daily

Cmax decreased 7%, AUC increased 1%, Cmin increased 13%
Tenofovir alafenamide ATV 703 Green: Administer standard doses Administer standard doses

Cmax increased 77%, AUC increased 91%

 300 mg + 100mg ritonavir once daily

Cmax decreased 2%, AUC decreased 1%
Tenofovir alafenamide DRV/r 702 Green: Administer standard doses Administer standard doses

Cmax increased 42%, AUC increased 6%

 800 / 100 mg once daily

Cmax decreased 1%, AUC increased 1%, Cmin increased 13%
Tenofovir alafenamide (TAF)
Subscribe to Tenofovir Alafenamide